Yield10 Bioscience Inc
NASDAQ:YTEN
Yield10 Bioscience Inc
NASDAQ:YTEN
Price:
0.2299 USD
6.44%
Market Closed
Updated:
May 2, 2024
P/S
Price to Sales
Price to Sales
59.1
Current
102.5
Median
8.1
Industry
Lower
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=59.1
Market Cap
/
3.5m
Revenue
60k
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| US |
|
Yield10 Bioscience Inc
NASDAQ:YTEN
|
3.5m USD | 59.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.3B USD | 5.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.1B USD | 5.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.8B USD | 10.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
101.7B USD | 7.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 3 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.8B USD | 6.7 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
1.5
2-Years Forward
P/S
0.9
3-Years Forward
P/S
0.1
You don't have any saved screeners yet
